Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Mar 25;15:170. doi: 10.1186/s12885-015-1140-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Liu et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Target binding activity of HB-002.1. Target binding activity of intact as well as deglycosylated HB-002.1 was analyzed by ELISA. (A) Binding to VEGF-A was compared to bevacizumab and Flt1(2). hIgG-Fc was used as negative control. (B-C) Binding to VEGF-B (B) and PIGF (C) was compared with rhVEGFR1-Fc. (D) Kinetic binding affinity was measured by equilibrium binding assays that measures unbound HB-002.1 or bevacizumab after incubation of 0.5 nM of HB-002.1 or bevacizumab with varying amounts of VEGF-165. (E) HB-002.1 deglycosylated by treatment with N-glycosidase F (D) or not deglycosylated (ND) was separated by SDS-PAGE under reducing or non-reducing conditions and visualized by staining with Coomassie Brilliant Blue. (F) VEGF-A binding affinity was compared between intact (non-digested) and deglycosylated (digested) HB-002.1.